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Pheochromocytoma (PCC), a rare neuroendocrine tumor, shows a prevalence ranging between 0.1% and
0.6% in individuals suffering from hypertension. To date, an increasing number of patients with hered-
itary forms or subclinical PCCs have been diagnosed. We reviewed the main controversies and the most
recent updates, especially inheritance genetics and surgical management. According to the “rule of 10”,
in 1/10 patients with pheochromocytoma it is malignant, in 1/10 of cases the tumor is bilateral, in 1/10
extra-adrenal and in 1/10 familial. Surgical resection, the only curative treatment, carries a high risk of
hypertensive crises due to massive catecholamine release. Alpha 1 blocker therapy, alone or in combi-
nation with beta blockers, calcium antagonists, and plasma volume expansion, is the most commonly
used preoperative treatment protocol. Minimally invasive adrenalectomy (laparoscopic and retro-
peritoneoscopic) allows earlier mobilization and recovery, reducing the risk of pulmonary infections
and thromb-oembolic complications, and is associated with lower morbidity and mortality rates than
traditional surgery; it is currently considered the gold standard for the treatment of adrenal tumors
6 cm in diameter and weighing < 100 g. Genetic testing will increasingly be the key factor in estimating
the life-long risk for development of recurrent disease, contralateral disease or malignant dedifferenti-
ation, thus inﬂuencing follow-up protocols.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Pheochromocytoma (PCC) is a rare neuroendocrine tumor
originating from the adrenal medulla or from chromafﬁn cells in
sympathetic ganglia, and is most common in women in their 40s
and 50s, with an incidence in the United States of 2e8 cases per
million per year [1e3]. Surgical resection, the only curative treat-
ment, carries a high risk of hypertensive crises [4,5]. 1/10 patient
has a malignant PCC, in 1/10 of cases the tumor is bilateral, in 1/10
extraadrenal and in 1/10 familial [6e9].
It has been shown that minimally invasive adrenalectomy (MA),
allowing earlier mobilization and recovery, is associated with lowergiovanni.conzo@hotmail.it
by Elsevier Ltd. All rights reservedmorbidity and mortality rates than traditional surgery [10].
Improved perioperative management resulted in a signiﬁcant
reduction of complications associated with cardiovascular hemo-
dynamic lability. However, either open or laparoscopic surgical
treatment of PCC is still at a high risk of intra-operative blood loss,
visceral lesions, and possible adverse cardiovascular events
[4,5,11e13,14,15].
Here we review the main controversies and the most recent
updates about PCC, especially inheritance genetics and surgical
management.2. Genetics
In the hereditary form, PCC is usually part of more complex
clinical syndromeswhose causative genes have been identiﬁed. The
most common hereditary causes of PCC and paraganglioma include.
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HippeleLindau syndrome (VHL), neuroﬁbromatosis type 1 (NF1)
and familial pheochromocytoma/paraganglioma syndromes.
Multiple Endocrine Neoplasia (MEN) type 2 is characterized by a
life-long risk of developing medullary thyroid carcinoma (MTC),
which occurs in more than 95% of patients. PCC is associated with
two of the MEN2 clinical subtypes, MEN2A and MEN2B, but rarely
in familial MTC (FMTC).
MEN2 is an autosomal dominant inherited syndrome with an
incidence estimated at 1 in 35,000 individuals. Germline mutations
of the REarranged during Transfection (RET) proto-oncogene are
responsible for the disease, as recognized nearly 20 years ago. The
RET proto-oncogene codes for a receptor tyrosine kinase required
for the development of neural-crest derived cells, the urogenital
system, and the central and peripheral nervous systems, notably
the enteric nervous system [16,17]. The receptor has a large extra-
cellular domain containing a series of cadherin-homology domains
and a cysteine-rich region, a transmembrane domain, and an
intracellular tyrosine kinase domain that is required for its phos-
phorylation and downstream signaling. RET activation leads to
stimulation of multiple downstream pathways, including mitogen-
activated protein kinase and extracellular signal- regulated kinase,
phosphoinositide 3-kinase and protein kinase B, signal transducer
and activator of transcription 3, proto-oncogene tyrosine-protein
kinase Src1 and focal adhesion kinase, all of which promote cell
growth, proliferation, survival, and/or differentiation [18]. MEN2-
associated mutations are located in exons 10, 11 or 13e16 of the
gene; mutations in exons 5 and 8 have also but rarely been re-
ported. The large majority is dominant and heterozygous, cause
amino acid substitutions either in the extracellular or the tyrosine-
kinase domain of the receptor resulting into its constitutive acti-
vation in the absence of ligands and co-receptors.
Strong genotypeephenotype correlations exist such that the
codon where the mutation occurs can be used to predict the MEN2
subtype, the risk for a PCC, the occurrence of hyperparathyroidism
and the age of onset and aggressiveness for MTC. PCC occurs in up
to 50% of individuals with MEN2A and MEN2B bearing mutation of
codon 634 (MEN2A) and codon 918 (MEN2B) respectively. It has not
been found in kindreds with mutations at codons 532e534, 630,
777 and 912. Because PCC is more commonly seen in association
with the high-risk mutations for MTC, its presence may imply a
more aggressive thyroid tumor. PCC tends to develop after MTC is
identiﬁed; however, there are well-documented examples of
MEN2-related PCCs presenting before MTC as the initial manifes-
tation of the syndrome. Less than 3% of cases of apparently sporadic
PCCs occurring before the age of 50 years are due to germline
mutations of the RET proto-oncogene [19]. MEN2-associated PCCs
are often detected by routine biochemical screening or for symp-
toms such as hypertension, palpitations, headache, tachycardia or
sweating. The typical age of onset is the third decade of life, 10e20
years earlier than the typical age of sporadic PCC development. The
American Thyroid Association has provided the management
guidelines for the initial diagnosis, therapeutic intervention and
long-term follow-up based on patients’ genotype and the current
understanding of the natural history of the disease associated with
each RET mutation [20].
Von HippeleLindau (VHL), a common cause of hereditary PCC,
should be one of the ﬁrst syndromes to be considered, particularly
if the patient is very young or if the tumor has noradrenergic
catecholamine secretion. Overall, VHL accounts for approximately
11% of apparently sporadic PCCs, most of them benign and intra-
adrenal, although extra-adrenal paragangliomas (PGLs) and ma-
lignant tumors can occur [21,22]. Von HippeleLindau syndrome is
an autosomal dominant disease characterized by PCC, renal can-
cers, retinal and/or cerebellar hemangioblastomas, cystic as well asneuroendocrine pancreatic tumors. VHL is classiﬁed into two main
types based on the risk of PCC. Type 1 is characterized by a low risk,
whereas type 2 by a high risk of PCC. This latter is further sub-
divided based on the risk of renal cell carcinoma: type 2A is asso-
ciated with a low risk while type 2B with a high risk of renal cell
carcinoma. Finally, type 2C is deﬁned as a PCC occurring without
other manifestations of the disease. The VHL gene is located on
chromosome 3p25, and its primary function is the regulation of
hypoxia-induced cell proliferation and angiogenesis. It acts as a
tumor suppressor gene and, in fact, the syndrome is caused by
inactivating germline mutations. In addition, most VHL-associated
pancreatic endocrine tumors display loss-of-heterozygosity (LOH)
of the VHL gene in the somatic tissue, supporting its role as sup-
pressor in tumor development.
Neuroﬁbromatosis type 1 (NF1) is also associated with heredi-
tary PCC. Patients with NF1 present manifestations that are obvious
at physical examination, most commonly including café-au-lait
macules, neuroﬁbromas and axillary and inguinal freckling by the
time they are at risk of developing a PCC [23]. Genetic testing is thus
generally not necessary to establish a correct NF1 diagnosis. NF1 is
a large gene of 60 exons, located on chromosome 17q11.2 coding for
the protein neuroﬁbromin. The gene, discovered in 1990, has one of
the highest spontaneous mutation rates in the human genome,
including missense, nonsense, and splice- site mutations as well as
intragenic deletions (indels) and chromosomal rearrangements.
NF1 is mainly expressed in the nervous system, where it represses
cell proliferation by promoting the conversion of RAS into its
inactive form, thereby inhibiting the oncogenic RAS/RAF/MAPK
signaling cascade [24]. Neuroﬁbromin also inhibits the PI3K/AKT/
mTOR pathway via RAS suppression (Max), implying that NF1
functions as a classical tumor suppressor gene. PCC only rarely
develops in NF1 and tends to behave as a sporadic pheochromo-
cytoma. The average age of onset is in the fourth decade, but it can
also occur in childhood and examples of multigenerational PCCs
have been reported. Most NF1-associated PCCs produce norepi-
nephrine and noradrenergic symptomatology; however, 22% have
no symptoms related to excessive catecholamine secretion.
Approximately 11e12% of such tumors are malignant, 10% are
bilateral and over 94% have an intra-adrenal localization [25].
During the last decade, mutations in the genes coding for the
different subunits of the succinate dehydrogenase (SDH) complex
have been linked to Hereditary pheochromocytoma/paraganglioma
(PCC/PGL) syndromes. Subsequent genetic screenings have
revealed that about 30% of PCCs and PGLs are caused by such
germline mutations [26]. In addition, several novel susceptibility
genes, such as transmembrane protein 127 (TMEM127) and MYC-
associated factor X (MAX), have been added to the list. These
newly identiﬁed predisposing genes seem, at ﬁrst glance, to have
entirely different functions but in spite of this, malfunction of their
different gene products can give rise to clinically and histologically
undistinguishable tumors. Nevertheless, some clinical featuresmay
be quite different: for instance, patients with SDHB mutations have
considerably a higher risk of malignancy than many other PCC/PGL
patients. Familial paragangliomatosis is associated with germline
mutations of the genes coding for the various subunits of the suc-
cinate dehydrogenase (SDH), a mitochondrial enzyme complex
consisting of four subunits: SDHA, SDHB, SDHC and SDHD, all of
which are encoded by nuclear genes [27]. The enzyme, also known
as mitochondrial complex II, is involved in the tricarboxylic acid
cycle, where it catalyzes the oxidation of succinate to fumarate, and
in the respiratory electron transfer chain, where it transfers elec-
trons to coenzyme Q. SDHA is located on chromosome 5p15.33,
consists of 15 exons and codes for a protein that functions as a part
of the enzyme catalytic core and contains the binding site for
succinate. The other part of the catalytic domain, which also forms
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gene of eight exons located on chromosome 1p36.13. SDHC on
chromosome 1q23.3 and SDHD on chromosome 11q23.1 contain
six and four exons, respectively, and code for two hydrophobic
proteins that anchor the complex to the mitochondrial inner
membrane. The link between SDH and neuroendocrine tumors was
ﬁrst established in the year 2000, when germline mutations in
SDHDwere discovered in patients with familial PGLs [28]. Germline
mutations in the SDH genes give rise to the familial PCC/PGL syn-
drome, sometimes only referred to as familial PGL. The syndrome
can be divided into PGL1, PGL2, PGL3, and PGL4, caused by muta-
tions in SDHD, SDHAF2, SDHC, and SDHB, respectively, all inherited
in an autosomal dominant manner with varying penetrance. The
prevalence of the PCC/PGL syndrome is unknown, but it is esti-
mated to be 1:50,000 to 1:20,000, the majority represented by
PGL1 and PGL4. Apart from PCCs and PGLs, SDHB mutations have
been associated with renal cell carcinoma. Mutations in SDHB,
SDHC, and SDHD can give rise to the Carney-Stratakis syndrome,
characterized by the dyad PGLs and gastrointestinal stromal tumors
(GISTs). Very recently, SDHA mutations have been reported in two
patients with GISTs but without PGLs. SDHDmutations (PGL1)most
frequently predispose to parasympathetic, often multifocal PGLs,
but also to sympathetic PGLs and PCCs. Several studies have gath-
ered information about tumor characteristics in patients with PCC/
PGL syndrome [29,30].
The transmembrane protein 127 (TMEM127) gene has been
found mutated in hereditary PCCs and identiﬁed as a PCC suscep-
tibility locus in 2005. However, no speciﬁc syndrome has been
linked toTMEM127.Other tumors, includingMTC, breast cancer, and
myelodysplasia, have been identiﬁed in carriers of TMEM127 mu-
tations, but a causal relationship between the tumors and the mu-
tations remains to be established [31]. A clear family history is
reported in only a fourth of the patients suggesting an incomplete
penetrance; in a single family, the penetrance of PCC of 64% by the
age of 55 years is also reported. TMEM127 is formed by four exons
located at 2q11.2 coding for a transmembrane protein that acts as a
negative regulator of mechanistic target of rapamycin, formerly
mammalian target of rapamycin (mTOR), thus linking a critical
signaling pathway for cell proliferation and cell death to the initia-
tion anddevelopment of PCC. Bothmissense andnonsense germline
mutations of TMEM127 have been reported along with LOH of the
gene in tumors of all testedmutation carriers, supporting the notion
that it functions as a tumor suppressor through the classical two- hit
model. Among 990 patients with PCC or PGL, negative for RET, VHL,
and SDHB/C/D mutations, TMEM127 mutations are detected in 20
cases (2.0%), all of which have PCC. In another study only one
additional PCC patient with a TMEM127 mutation has been found
while no TMEM127 mutations are detected in 129 sympathetic and
60 parasympathetic PGLs [32]. In a recent study, germline missense
variants are reported in two out of 48 patients with multiple PGLs,
one of which also displays bilateral PCC [33]. Summarizing the 23
reported patients, all but one (96%) has PCC and 39% have bilateral
PCCs, two (9%) have PGL, one of which sympathetic and the other
multiple parasympathetic PGLs. The mean age at presentation is 43
years, and one patient (4%) shows a malignant tumor.
MYC-associated factor X (MAX) mutations segregate with the
disease in families with PCC, but no speciﬁc syndrome has been
described yet. A paternal origin of the mutated allele in the inves-
tigated cases, together with the absence of PCC in individuals who
inherit a mutated allele from their mother, may suggest a paternal
transmission of the disease similar to PGL1 (SDHD) and PGL2
(SDHAF2). Comino-Mendez et al. [34] have reported 12 PCC pa-
tients with MAX mutations, three of which identiﬁed with the
exome next generation sequencing and four of which as probands’
relatives. The remaining ﬁve have been found in a subsequentscreening of 59 PCC patients lacking mutations in other known
susceptibility genes but suspected to have hereditary disease. Of
the 12 patients, eight (67%) have bilateral PCC and the mean age at
presentation is 32 years. Notably, 25% of the patients present
metastasis at diagnosis, suggesting that MAX mutations are asso-
ciated with a high risk of malignancy.
MAX is a gene of ﬁve exons, located on chromosome 14q23.3
that codes for a transcription factor, MAX, belonging to the basic
helix-loop-helix leucine zipper (bHLHZip) family. It plays an
important role in the regulation of cell proliferation, differentiation
and death as a part of the MYC/MAX/MXD1 network [35,36]. Some
tumors can grow in the absence of MYC-MAX dimers and imply
that MAX can function as a tumor suppressor, a role that has most
recently conﬁrmed, as germline MAX mutations are discovered in
PCC patients by next-generation exome sequencing [35].
3. Preoperative management
a-adrenergic receptor antagonists, calcium channel blockers
and metyrosine are the most used drugs as preoperative protocol
therapy. Selective ⍺1 blockers have been introduced to avoid the
main side and delayed therapeutic effects of phenoxybenzamine, a
non-selective alpha blocker. Before alpha blockers were introduced
in the 1950s, perioperative mortality, currently limited to 0e6%
[10,37,38], ranged between 24% and 50% [39,40].
The ﬁrst drug therapy suggested was a combination of beta
blockers and phenoxybenzamine. In order to avoid its side effects,
selective alpha 1 blockers were used: ﬁrstly prazosin then terazosin
and doxazosin, which are currently widely used. Doxazosin, a
competitive selective alpha 1 antagonist, lipophilic with high
bioavailability and relatively long-acting, is administered once daily
[41,42]. P. Tauzin-Fin and C. Prys-Roberts reported a better blood
pressure (BP) and heart rate (HR) control with doxazosin thanwith
phenoxybenzamine, observing that an effective preoperative
adrenergic blockade does not prevent hypertensive crises but neu-
tralizes catecholamine effects [41,42]. Reports regarding preopera-
tive drug therapy outcomes show contradictory data. L.B. Perry, C.A.
Deoreo and A.R. Boutros did not observe any difference between
mortality rates of treated and untreated patients [43e45]. On the
contrary, J.C. Ulchaker, in 113 patients who underwent surgery be-
tween 1977 and 1994, reported no mortality among preoperatively
treated patients, but more severe cardiovascular complications,
concluding that preoperative alpha adrenergic blockade is not
essential [5], according to K.A. Newell [46]. However, J. Steinsapir
reports 2 deaths among patients who underwent surgery without
preoperative therapy [47]. Y. Zhu, in a recent series of 67 cases, re-
portedmore stable perioperative hemodynamic changes in patients
pretreated with doxazosin, irrespective of phenoxybenzamine [48].
Also T.N. Weingarten concluded that non selective a-blockade pro-
duces a better decrease of intra-operative hypertension, but it is
followed by a longer hypotension, requiring a greater use of vaso-
pressors [49]. Calcium antagonists, inhibiting calcium- dependent
norepinephrine release, are also very effective in the preoperative
blood pressure and peripheral vascular resistance control [50].
Alpha 1 blocker therapy, alone or in combination with beta
blockers, calcium antagonists, and plasma volume expansion, is
therefore the most commonly used treatment protocol, as
conﬁrmed by van der Horst-Schrivers [2]. In our experience, a
treatment with doxazosin (2e10 mg daily) was administered for at
least 2 weeks preoperatively, in more than 60 cases of LA. Selective
alpha 1 blockers resulted very effective in BP and HR control. Pre-
operative adrenergic blockade did not guarantee hemodynamic
stability, but allowed an optimal pharmacological control of hy-
pertensive crises, in absence of major adverse cardiovascular events
[51,52].
Table 1
Results of minimally invasive adrenalectomy in patients with pheocrhomocytomas.
Authors Patients
(number)
Operative time
(minutes)
Blood
loss (ml)
Conversion (%) Morbidity (%) Mortality (%)
M. Gagner (’96) 23 230 e 0 22 0
M.K. Walz (’02) 52 116  52 100 0 23 0
D.E. Jaroszewski (’03) 47 140 80 11 4.8 0
A.W. Kim (’04) 26 191 276 4 23 0
K.W. Kercher (’05) 80 169 97 0 7.5 0
Y. Naya (’05) 23 192.7 130 4.34 0 0
A. Toniato (’07) 40 78 100 3 2.5 0
M.J. Mellon (’08) 11 181.4 e 1.4 10 0
K.A. Perry (’09) PCC<6 cm 22 189 68 9.1 13.6 0
K.A. Perry (’09) PCC>6 cm 8 212 130 37.5 12.5 0
G.Y. Meyer-Rochow (’09) 36 183 e 2.7 13.9 0
L.N. Castilho (’09) 24 126 e 0 16.7 0
P. Nau (’10) 33 142 e 12.1 6 0
W.T. Shen (’12) 102 186 e 3 13.7 0
Y.M. Carter (’12) 25 e e 0 0 0
Conzo (’12) 60 165 130 5 8.3 0
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PCC surgery remains hazardous and multidisciplinary high
volume centres may obtain the best results. MA, since ﬁrst
description by M. Gagner in 1992 (laparoscopic) and lately by M.K.
Walz in 1995 (retroperitoneoscopic), associated with a lower
morbidity rate, shorter hospital stay, and a more rapid recovery
than “open” surgery, is currently considered the gold standard for
the treatment of adrenal tumors 6 cm in diameter and
weighing < 100 g. Most beneﬁts are well known [5,51e53]. M.M.
Murphy, in a recent review, reported statistically signiﬁcant lower
morbidity and mortality rates than traditional surgery, due to
reduced postoperative pulmonary infections and thrombo-embolic
complications [10]. Even though improved perioperative manage-
ment, advances in anesthesiology and surgery have allowed a sig-
niﬁcant reduction in mortality and morbidity, PCC surgery is still a
challenge, especially for large lesions, because of the extensive
vascularization, the difﬁculties inmobilization and dissection of the
adrenal gland, the tenacious adhesions to adjacent structures.
Moreover, the risk of malignancy and of local recurrence, were
considered in the past as a contraindication to laparoscopic treat-
ment of PCC >6 cm [53]. Nevertheless, according to R. Bellantone,
PCC >6 cm in diameter becomes malignant less frequently than
other adrenal lesions of the same size do, and probably size cannot
itself be an absolute contraindication for LA [54]. Currently, in-
dications to LA for lesions >6 cm is still a matter of debate, and
experienced endocrine surgeons are divided between supporters
[3,13,38,54] and detractors [55,56]. In our experience, LA was safe
for most patients with PCC, even in selected cases >6 cm without
preoperative suspicion of malignancy. Laparoscopic surgery was
associated with acceptable morbidity rate, similar to those previ-
ously reported for other adrenal diseases [57,58]. We observed a
higher incidence of intraoperative hypertensive crises and of con-
version to open surgery in PCC larger than 6 cm, but statistically
signiﬁcant differences were never reported. Blood loss, operative
time and incidence of complications did not seem to be affected by
PCC size. So we propose to treat cautiously even PCC 6e8 cm in
diameter by LA, if great care is adopted to avoid capsular disruption,
and a prompt conversion is considered in case of technical difﬁ-
culties to reduce patient risks [13,51,59e63]. Literature data
conﬁrm the effectiveness and safety of MA (Table 1).
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